Stratos Wealth Partners LTD. Reduces Position in Shire PLC (SHPG)

Stratos Wealth Partners LTD. reduced its position in shares of Shire PLC (NASDAQ:SHPG) by 28.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,896 shares of the biopharmaceutical company’s stock after selling 749 shares during the period. Stratos Wealth Partners LTD.’s holdings in Shire PLC were worth $290,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Bedell Frazier Investment Counseling LLC lifted its holdings in Shire PLC by 6.1% during the 3rd quarter. Bedell Frazier Investment Counseling LLC now owns 27,995 shares of the biopharmaceutical company’s stock worth $4,287,000 after purchasing an additional 1,607 shares during the last quarter. Comerica Bank lifted its holdings in Shire PLC by 3.4% during the 3rd quarter. Comerica Bank now owns 21,431 shares of the biopharmaceutical company’s stock worth $3,124,000 after purchasing an additional 712 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Shire PLC by 93.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 10,674 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 5,149 shares during the last quarter. Pitcairn Co. lifted its holdings in Shire PLC by 26.5% during the 3rd quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock worth $293,000 after purchasing an additional 401 shares during the last quarter. Finally, Breton Hill Capital Ltd. lifted its holdings in Shire PLC by 19.4% during the 3rd quarter. Breton Hill Capital Ltd. now owns 5,499 shares of the biopharmaceutical company’s stock worth $842,000 after purchasing an additional 893 shares during the last quarter. 18.64% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Stratos Wealth Partners LTD. Reduces Position in Shire PLC (SHPG)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/20/stratos-wealth-partners-ltd-reduces-position-in-shire-plc-shpg.html.

Several brokerages have weighed in on SHPG. Zacks Investment Research raised Shire PLC from a “sell” rating to a “hold” rating in a report on Friday, October 27th. ValuEngine cut Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Cowen and Company set a $225.00 price objective on Shire PLC and gave the company a “buy” rating in a report on Sunday, October 29th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $222.00 price objective on shares of Shire PLC in a report on Thursday, September 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 price objective on shares of Shire PLC in a report on Sunday, October 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Shire PLC presently has a consensus rating of “Buy” and an average target price of $212.18.

Shire PLC (NASDAQ:SHPG) opened at $147.37 on Monday. Shire PLC has a 52 week low of $137.17 and a 52 week high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $44,273.93, a price-to-earnings ratio of 10.14, a PEG ratio of 0.82 and a beta of 1.60.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $3.70 billion for the quarter. During the same quarter in the previous year, the business posted $3.17 EPS. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. sell-side analysts expect that Shire PLC will post 15 earnings per share for the current year.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply